{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-126509","form_type":"8-K","ticker":null,"cik":"0001661460","company_name":"Poseida Therapeutics, Inc.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.478712+00:00","generated_at":"2026-06-03T02:58:43.288741+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Poseida & Astellas/Xyphos enter allogeneic CAR-T collaboration; $50M upfront, $550M milestones","bullets":["$50M upfront payment ($6M advanced for R&D); up to $550M in development/sales milestones plus low double-digit tiered royalties.","Two allogeneic convertible CAR-T candidates targeting solid tumors combining Poseida’s platform with Xyphos’ ACCEL technology.","Xyphos responsible for development/commercialization; Poseida performs research through IND-enabling data package.","Expands existing relationship; Astellas made strategic investment in Poseida in August 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-126509","json":"https://secwatch.observer/filing/0001193125-24-126509.json","markdown":"https://secwatch.observer/filing/0001193125-24-126509.md","text":"https://secwatch.observer/filing/0001193125-24-126509.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661460/000119312524126509/0001193125-24-126509-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661460/000119312524126509/d813637d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:58:43.288741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12478d4624820138a7440dcf8449e2015f5fc80a","claim":"Poseida Therapeutics, Inc. entered into Collaboration Agreement with Xyphos Biosciences, Inc. valued at $50.0 million (effective 2024-04-30).","evidence_excerpt":"On April 30, 2024, Poseida Therapeutics, Inc. (the “Company”) and Xyphos Biosciences, Inc., a wholly-owned subsidiary of Astellas Pharma Inc. (“Xyphos”), entered into a collaboration and license agreement (the “Collaboration Agreement”),","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312524126509/0001193125-24-126509-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Xyphos Biosciences, Inc."},{"label":"Value","value":"$50.0 million"},{"label":"Effective","value":"2024-04-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}